Mastering Immunity 2018

Monday 10 and Tuesday 11 September

Museum of Science, Boston, MA

Register today

Understand and manage immune responses in drug and vaccine development

 

Filmed Presentations from all our meetings are available online

Join our Mastering Immunogenicity LinkedIn Group

As targeted immune therapies grow in complexity, understanding and controlling immune regulation has never been more important in the design of therapeutics.

Join experts in both academic and commercial immunology at Mastering Immunity 2018 for a focussed conference to learn the latest developments in this fast-developing field covering multiple aspects of in the development of modern therapeutics. This focussed meeting is a forum for key people involved in wanting to characterize immune modulation following delivery of biologics and other therapies to come together to share knowledge, perspectives and discuss solutions to the complex challenges of immunity in this context. We will focus on manipulation and characterization of both desired (in immuno-oncology and vaccines) as well as unwanted immune responses (i.e. immunogenicity to biotherapeutics or viral vectors).

This meeting, of which the Mastering Immunogenicity series is part of, is now in its seventh consecutive year having also been held in Oxford, UK.  

This year's meeting held at the Museum of Science in Boston offers an unparalleled opportunity to meet and share information with like-minded scientists from other organizations, and to help shape the future of your R&D programs.

Download Full Conference Programme

Day 1 - Monday 10 September

8.30am

 

Arrival and registration

9.00am

 

Welcome and conference overview

9.10am

 

Dr. Marcus Butler, Assistant Professor, Princess Margaret Cancer Centre, UHN Toronto

"Optimizing Adoptive T cell Therapies"

9.50am

Dr. Marianne Stanford, VP Research, IMV

"De novo generation of tumor specific T cell responses utilizing a novel oncology driven delivery platform"

10.30am

 

Coffee and Networking

11.10am

 

Dr. Daniel Hui, Cell-based Assay Lead, Spark Therapeutics, Inc.

"Epitope Mapping of T Cell Responses against Adeno-associated Viral (AAV) Vectors for use in Gene Therapy"

11.50am

 

Dr. Pierre Tonnerre, Scientist, Gastrointestinal Unit, Massachussetts General Hospital, Boston

"Investigating exhausted T cell plasticity after removal of cognate antigen"

12.30pm

 

Lunch

2.00pm

Dr. Emilee Knowlton, ProImmune

"Epitope identification and clinical immune monitoring in gene therapy and immune oncology programs"

2.40pm

Dr. Priya Sriraman, Senior Director, Biologics DMPK, Celgene

"Qualification of an ELISPOT assay to monitor product specific cellular immunogenicity in patients"

3.20pm

 

Coffee and networking

3.40pm

Dr. Zuben Sauna, Principal Investigator, FDA

"Use of the MHC Associated Peptide Proteomic (MAPPs) assay to understand clinical outcomes associated with the use of Factor VIII in the treatment of Hemophilia A"

4.20pm

 

Dr. Shahla Abdollahi, Senior Scientist, Celgene

"Mechanisms of Immune Modulation by the Gut Microbiome – Implications for Autoimmunity"

5.00-6.30

 

Drinks reception

 

Day 2 - Tuesday 11 September

9.00am

Dr. Amy Rosenberg, Director, Division of Therapeutic Proteins, CDER, FDA

"So You Think You Have Mastered Immunity? Cautionary Tales from The Immunology Revolution"

9.40am

Dr. Jeremy Fry, Director of Sales, ProImmune

"An integrated approach to managing immunogenicity risk and drug immune modulation"

10.20am

Dr. Inderpal Singh, Lead, Immunogenicity Prediction in Biologics, Assays & Technology, Teva Pharmaceuticals

"Immunogenicity risk assessment of process related impurities"

11.00am

 

Coffee and Networking

11.30am

Dr. Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb

"Immunogenicity risk assessment tool box for biologics drug development"

12.10pm

Dr. Sophie Tourdot, Associate Biomedicine Design, Pfizer Inc.

"Non-clinical immunogenicity risk assessment of therapeutic proteins"

12.50pm

 

Lunch

2.00pm

Dr. Jad Maamary, Associate Principal Scientist, Merck & Co.

"Immunogenicity to biotherapeutics in mono and combination therapies"

2.40pm

Dr. Andrea Ferrante, Eli Lilly

"In-silico prediction of immunogenicity: filling the gaps"

3.20pm

Dr. Rodd Polsky, GlaxoSmithKline

"Format and Interpretation of a Drug Tolerant Approach for Measuring Circulating Immune Complex and Free Anti-Drug Antibodies in Preclinical Studies"

4pm

 

Meeting Close

How will I benefit?

Education

Network

  • Learn the key issues facing drug developers

  • Be informed of the latest strategies for pre-clinical and clinical immune modulation

  • Quality by Design in drug development

  • Be informed of the latest technologies to keep ahead of the competition

  • Case studies

  • Exchange new ideas

  • Meet potential collaborators

  • Discuss current and developing challenges

  • Meet like-minded scientists from other organizations, and to help shape the future of your own R&D programs.

Feedback from previous conferences:

“Mastering Immunogenicity captured the breadth and depth of immunogenicity issues faced by industry today” (Tim Hickling, Pfizer)

“I also had a great time during the meeting. It was truly excellent in content and organization.” (Julio Delgado, University of Utah)

“It was a terrific event, with excellent speakers and great networking/brainstorming opportunities at the breaks and with the roundtable” (Valerie Quarmby, Genentech)

"Great first experience. I enjoyed the breadth of topics" (Laurent Malherbe, Eli Lilly)

 “Great speakers with diverse topics. I enjoyed the deep science and also the opinions from experts in the field” (Xiaoying Chen, Pfizer)

 "Covered a diverse array of subjects. I enjoyed the networking opportunities” (Shinu John, Moderna Therapeutics)

"Excellent event" (George Gunn, Janssen R&D)

"Really liked the interactive environment. In-depth discussions with very relevant colleagues"

 "I really enjoyed the very good quality, sparkling diversity, but still keeping focus"

"Very nice and comprehensive topics in this symposium. I have learnt a lot from it." (Pu Shi, Takeda)

"This is a fantastic conference that is a good mix of vaccine and biotherapeutic folks. Facilitates learning and collaboration." (Priya Sriraman, Celgene)

 "I really enjoyed the very good quality, sparkling diversity, but still keeping focus"

Conference Venue

Boston Museum of Science, 1 Science Park, Boston, MA 02114

The city of Boston is an international center of higher education and a center for medicine and biotechnology, and consequently is a fitting location for ProImmune's Mastering Immunity conference. This year, the venue is the Museum of Science, one of the world's largest science centers, and New England's most highly attended cultural institution.

The meeting will take place in the Skyline Room on the Museum's top floor, with panoramic views of the Charles River, Back Bay, Boston and Cambridge through two walls of floor-to-ceiling windows.

 

Accommodation

Delegates are responsible for arranging their own accommodation. The following are suggested options for accommodation in the vicinity of the conference venue: 

Royal Sonesta Hotel: http://sonesta.com/corporate
Kimpton Hotel Marlowe: http://www.hotelmarlowe.com

Fairfield Inn & Suites by Marriott: http://www.mariott.com 

Hotel Marlowe: http://www.hotelmarlowe.com
Hampton Inn Boston Cambridge: http://hamptoninn3.hilton.com

Transportation
For drivers: Delegates are offered free parking validation at the Museum Car Park.

For rail users: the closest T stop is 'Science Park' on the Green Line (4 min walk); for the Red Line use 'Kendall Square' (20 min walk).

All Conference Enquiries

Email: enquiries@proimmune.com

Telephone (toll free): USA & Canada +1 888 505 7765
All other countries +44 (0) 870 042 7279